The U.S. Food and Drug Administration’s vaccine advisory panel is set to meet on Thursday to consider an emergency use authorization, or EUA, for the COVID-19 vaccine jointly developed by Pfizer and German company BioNTech.

Despite newly reported deaths nationwide topping a thousand per day, the FDA doesn’t seem to have been in a hurry to review the companies’ vaccine, which proved 95% effective in clinical trials. The meeting will come nearly three weeks after the two companies submitted their request for an EUA. While the race for a COVID-19 vaccine has moved with unprecedented speed, the regulatory state hasn’t followed suit.